 |
Chairman and President
Yuet Kan, M.D.
University of California, San Francisco
San Francisco, CA
Dr. Kan is the Louis K. Diamond professor of hematology at the University of California – San Francisco. He is regarded as a pioneer of applying molecular biology and genetics into clinical medicine. Kan was the first to establish that a single DNA mutation could lead to a human disease and the first to diagnose a human disease by using DNA. He also discovered DNA polymorphism, which is widely used in genetic analysis for human diseases. Kan has won numerous prestigious awards, including the Lasker Award and the Shaw Prize.
|
 |
Founding Chairperson of the Board and President Emeritus
Bayard D. Clarkson, M.D.
Memorial Sloan-Kettering Cancer Center
New York, NY
Dr. Clarkson is head of the Laboratory of Hematopoietic Cell Kinetics at Memorial Sloan-Kettering Cancer Center. His laboratory has been devoted to understanding the growth and differentiation properties of leukemia cells and progenitor cells. By studying the core biological principles that govern and fuel cancer formation, Clarkson and his colleagues were among the first to develop and optimize treatment programs for adults with acute leukemias and lymphomas. He has also made significant contributions to the understanding of cancer biology, especially in the area of cancer stem cells. His board directorships include the Havens Relief Fund Society, Cold Spring Harbor Laboratory, and Clarkson University.
|
 |
Secretary-Treasurer and CEO
Margaret Foti, Ph.D., M.D. (h.c.)
American Association for Cancer Research
Philadelphia, PA
Dr. Foti has been chief executive officer of American Association for Cancer Research since 1982. She is also past president of several key cancer organizations including the National Coalition for Cancer Research, as well as other organizations including the Society for Scholarly Publishing, and the Council of Biology Editors.
|
 |
Vice-Chairman
William H. Mears Jr., J.D., CPA
Brown Brothers Harriman Trust Co., LLC
New York, NY
Mr. Mears is regional trust head of Brown Brothers Harriman Trust, LLC. He is a past president of the Estate Planning Council of New York City and past chair of the Deferred Giving Committee of the New York Philharmonic. Mears is vice-chair of the AACR Foundation and chairperson of the Foundation's Planned Giving Committee.
Trustees
|
 |
Beverly W. Aisenbrey
Frederic W. Cook & Co., Inc.
Tarrytown, NY
Ms. Aisenbrey is a managing director in the New York office of Frederic W. Cook & Co. Inc. She has been with the firm since 1982 and is on their Board of Directors. She works with companies in designing performance-based compensation programs, primarily annual incentives, long-term incentives and stock ownership programs. Aisenbrey also writes and speaks frequently on the topic of management and board of directors' compensation. She is a member of the Dean’s Advisory Board at Rutgers Business School and a former trustee of Rutgers University.
|
 |
Carlos L. Arteaga, M.D.
Vanderbilt-Ingram Cancer Center
Nashville, TN
Dr. Arteaga is a professor of medicine and cancer biology at Vanderbilt University School of Medicine where he holds the Donna S. Hall chair in breast cancer research. He also serves as associate director for clinical research and director of the Breast Cancer Research Program at Vanderbilt-Ingram Cancer Center. Arteaga’s research interests include oncogene signaling and molecular therapeutics in breast cancer with an emphasis on targeted therapies, mechanisms of drug resistance, translational research and investigator-initiated clinical trials. He is a principal investigator on the Stand Up To Cancer Dream Team, “Targeting the PI3K Pathways in Women’s Cancers.” Arteaga is a former member of the AACR Board of Directors and is the AACR’s president-elect for 2013-2014.
|
 |
Elizabeth H. Blackburn, Ph.D.
University of California, San Francisco
San Francisco, CA
Dr. Blackburn is the Morris Herzstein professor in the Department of Biochemistry and Biophysics at the University of California, San Francisco and a non-resident fellow of the Salk Institute. Her research focuses on cancer and aging, specifically on the role of telomeres. In 2009, Blackburn shared the Nobel Prize in Medicine or Physiology for the discovery of how chromosomes are protected by telomeres and telomerase. She serves on the Scientific Advisory Committee for Stand Up To Cancer and was the 2009-2010 president of the AACR.
|
 |
Gary L. Countryman
Liberty Mutual Insurance Company
Marlborough, MA
Mr. Countryman is chairman emeritus of the board of directors of Liberty Mutual Insurance Company. Countryman spent nearly 40 years with the company, attaining the positions of CEO and chairman before his retirement in 2000. In his years at Liberty Mutual, he transformed the company from a U.S. domestic property and casualty insurer into a leading international financial services group of companies. Countryman is involved at a high level in many nationally recognized organizations, including as a trustee and former chairman of the Dana-Farber Cancer Institute.
|
 |
Raymond DuBois, M.D., Ph.D.
Biodesign Institute - Arizona State University
Tempe, AZ
Dr. DuBois is executive director of Arizona State University’s Biodesign Institute. He also holds the Dalton Chair in ASU’s School of Health Solutions with joint appointments in chemistry and biochemistry, and a joint appointment at the Mayo Clinic where he co-leads the cancer prevention program. Dubois previously served as provost and executive vice president of Academic Affairs at M. D. Anderson Cancer Center, as well as director of the Vanderbilt-Ingram Cancer Center. Dubois was the 2008-09 president of the AACR.
|
 |
Judy E. Garber, M.D., M.P.H.
Dana-Farber Cancer Institute
Boston, MA
Dr. Garber is director of the Cancer Risk and Prevention Program at the Dana-Farber Cancer Institute, associate professor of Medicine at Harvard Medical School, and associate physician of medicine and attending physician of medical service at Brigham and Women’s Hospital. Her research focuses primarily on breast cancer risk assessment and risk reduction. Garber is the recipient of numerous professional awards, and is an elected member of the American Society for Clinical Investigation. She is a member of the Stand Up To Cancer Innovative Research Grants Review Committee, as well as several other AACR committees and editorial boards. Garber was the 2011-2012 president of the AACR.
|
 |
Nance Guilmartin
Author, Consultant
Boston, MA
Ms. Guilmartin has designed and launched such successful public service initiatives as the Designated Driver Program. She is the author of the book Healing Conversations: What to Say When You Don't Know What to Say, a collection of stories and advice to help friends, family and colleagues understand how to support one another during times of crisis and change.
|
 |
William N. Hait, M.D., Ph.D.
Janssen Research & Development, LLC
Raritan, NJ
Dr. Hait is global head, Janssen Research & Development, LLC, the global research and development arm of Janssen, the pharmaceutical companies of Johnson & Johnson. Formerly, he was director of the Cancer Institute of New Jersey and professor of medicine and pharmacology and associate dean for oncology programs at the University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School. He is a member of the medical advisory board of the New Jersey Breast Cancer Coalition and the scientific advisory boards of several universities. Hait was the 2007-2008 president of the AACR and is currently serving as AACR’s treasurer.
|
 |
Tyler E. Jacks, Ph.D.
Massachusetts Institute of Technology
Cambridge, MA
Dr. Jacks is the David H. Koch professor of biology at M.I.T., director of the David H. Koch Institute for Integrative Cancer Research at M.I.T. and an investigator with the Howard Hughes Medical Institute. He also serves on the boards of directors of Amgen and Thermo Fisher Scientific, and is chair of the National Cancer Advisory Board. His research interests are in the genetic events that contribute to the development of cancer, particularly the oncogene K-Ras. Jacks was the 2009-2010 president of the AACR.
|
 |
V. Craig Jordan, O.B.E, Ph.D., D.Sc., F.Med.Sci.
Lombardi Comprehensive Cancer Center of Georgetown University
Washington, DC
Dr. Jordan is scientific director and vice chairman of oncology at the Lombardi Comprehensive Cancer Center of Georgetown University. Specializing in antihormonal drugs for breast cancer treatment and prevention (tamoxifen and raloxifene), he was previously vice president and research director for Medical Science and Alfred G. Knudson chair of cancer research at the Fox Chase Cancer Center, Diana Princess of Wales professor at Northwestern University and director of the Lynn Sage Breast Cancer Research Program for the Robert H. Lurie Comprehensive Cancer Center. A member of the National Academy of Sciences, Jordan is founding chairperson of the AACR Foundation President’s Circle.
|
 |
Eleanor D. Kress
Wilmington Trust Retirement and Institutional Services Co.
New York, NY
Ms. Kress is a vice president at Wilmington Trust Retirement and Institutional Services Co. She manages legal and compliance activities regarding investment vehicles for corporate and governmental retirement plans, and reviews and negotiates agreements with investment advisory firms. Kress serves as chair of Wilmington Trust’s Collective Fund Investment Sub-Committee, and as a member of the company’s Collective Investment Fund Management Committee. Kress sits on the board of directors of Cannon Point North Inc., and the North Carolina Society of New York.
|
 |
Sherry Lansing
The Sherry Lansing Foundation
Hollywood, CA
Ms. Lansing is the founder and CEO of the Sherry Lansing Foundation, a philanthropic organization focused on cancer research, health and education. Ms. Lansing was the chair of the Motion Picture Group of Paramount Pictures from 1992 to 2005. Currently, Lansing serves on the boards of Friends of Cancer Research, The Lasker Foundation, Teach for America, The Carter Center, and Stop Cancer. Lansing is also a regent of the University of California.
|
 |
Laurence J. Marton, M.D.
University of California, San Francisco
San Francisco, CA
Dr. Marton is an adjunct professor in the Department of Laboratory Medicine at the University of California, San Francisco, and serves as a consultant to industry, government and academic institutions. He is a leading expert with extensive experience in the fields of cell growth and drug development. Marton was previously professor and chair of the Department of Laboratory Medicine at UCSF, and dean of the School of Medicine at the University of Wisconsin. In recent years, Marton has been a founder and CEO of the SLIL Biomedical Corporation, as well as a chief scientific officer and advisor to other biopharmaceutical companies. He is a member of the board of directors of Cancer Commons and of the California Heart Center Foundation.
|
 |
Frank McCormick, Ph.D.
University of California, San Francisco Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Dr. McCormick is director of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center. He holds the E. Dixon Heise distinguished professorship in oncology and the David A. Wood distinguished professorship of tumor biology and cancer research at UCSF. Additionally, he is the associate dean of the UCSF School of Medicine. McCormick pioneered cancer research looking at the molecular basis of cancer and how genes, when mutated or expressed at high levels, help turn normal cells into oncogenes. In 1992, he founded biotech company Onyx Pharmaceuticals and developed Nexavar, which is used to treat advanced renal cell carcinoma and hepatocellular carcinoma. His current research interests center on the Ras pathway and new ways of targeting this pathway for cancer therapy. McCormick was the 2012-2013 president of the AACR.
|
 |
David G. Nathan, M.D.
Dana-Farber Cancer Institute
Boston, MA
Dr. Nathan is president emeritus of Dana-Farber Cancer Institute, physician-in-chief emeritus of Children's Hospital and the Robert A. Stranahan distinguished professor of pediatrics at Harvard Medical School all in Boston. He is the recipient of numerous awards, including the National Medal of Science, 1990; the Annual Award for Excellence in Clinical Research, NIH, 1996; the Henry Stratton Medal, American Society of Hematology, 1995; the John Howland Medal of the American Pediatric Society 2003, the George Kober Medal of the Association of American Physicians 2006 and the John Stearns Medal for Lifetime Achievement in Medicine of the New York Academy of Medicine 2009.
|
 |
John E. Oxendine
Blackstar Management
Boca Raton, FL
Mr. Oxendine is president and CEO of Blackstar Management. He is an investor, operator and lender in the television broadcasting industry, with a primary focus upon investment in minority-owned or controlled companies. Oxendine formerly served as chief executive at Broadcast Capital Inc. He is currently chairman of Adopt–a-Classroom and the Palm Beach International Film Festival, and sits on the global advisory board of the Footprints Foundation.
|
 |
Charles L. Sawyers, M.D.
Memorial Sloan-Kettering Cancer Center
New York, NY
Dr. Sawyers is chair of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center and a professor in the Cell and Developmental Biology Program and the Department of Medicine at the Joan and Sanford Weill Graduate School of Medical Sciences of Cornell University. His research efforts are currently centered on investigating the signaling pathways that drive the growth of cancer cells, with an eye toward designing new treatment options for patients. Sawyers is a co-leader of the Stand Up To Cancer PI3K Dream Team and a Howard Hughes Medical Institute Investigator. He is the 2013-14 president of the AACR.
|
 |
Ellen Sigal, Ph.D.
Friends of Cancer Research
Washington, DC
Dr. Sigal is the founder and chairperson of Friends of Cancer Research. She serves on the board of directors of the Foundation for the NIH and the Entertainment Industry Foundation’s Oversight Committee for the Biomarker Discovery Project. She also serves on C-Change and is president of The Creative Community Task Force for Cancer Research For her efforts, Sigal has received such awards as the 1998 AACR National Leadership Award, the 1999 Sidney Kimmel Cancer Center National Leadership Award, and the 2004 Association of American Cancer Institutes Public Service Award.
|
 |
Daniel D. Von Hoff, M.D., F.A.C.P.
TGen
Phoenix, AZ
Dr. Von Hoff is physician-in-chief and director of Translational Research at the Translational Genomics Research Institute. He is a professor of medicine, pathology, molecular and cellular biology and director of the Arizona Health Sciences Center's Cancer Therapeutics Program and serves as chief scientific officer for U.S. Oncology and Scottsdale Healthcare's Clinical Research Institute. Von Hoff serves on the scientific advisory boards of numerous pharmaceutical and biotech companies. He served as the 1999-2000 president of the AACR.
|
 |
Geoffrey M. Wahl, Ph.D.
The Salk Institute for Biological Studies
La Jolla, CA
Dr. Wahl is a professor in the Gene Expression Laboratory at the Salk Institute for Biological Studies and an adjunct professor in the biology department at the University of California, San Diego. His research focuses on the signal transduction pathways that ensure the control of genetic stability in normal cells, as well as identifying, isolating and characterizing the cells that initiate cancer. Wahl serves on the board of directors of the Nicholas Conor Institute for Pediatric Cancer and the scientific advisory board of the Pancreatic Cancer Action Network. He served as the 2006-2007 president of the AACR.
|